X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ORCHID PHARMA LTD - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ORCHID PHARMA LTD NOVARTIS/
ORCHID PHARMA LTD
 
P/E (TTM) x 328.0 -0.2 - View Chart
P/BV x 36.4 0.2 23,974.1% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 NOVARTIS   ORCHID PHARMA LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ORCHID PHARMA LTD
Sep-13
NOVARTIS/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs758194 390.7%   
Low Rs57935 1,654.3%   
Sales per share (Unadj.) Rs228.4276.5 82.6%  
Earnings per share (Unadj.) Rs31.7-79.2 -40.1%  
Cash flow per share (Unadj.) Rs32.8-43.5 -75.4%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs297.153.9 550.9%  
Shares outstanding (eoy) m24.6970.45 35.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.90.4 706.8%   
Avg P/E ratio x21.1-1.4 -1,457.1%  
P/CF ratio (eoy) x20.4-2.6 -774.3%  
Price / Book Value ratio x2.22.1 106.0%  
Dividend payout %31.50-   
Avg Mkt Cap Rs m16,5058,067 204.6%   
No. of employees `0000.72.8 23.9%   
Total wages/salary Rs m1,4452,527 57.2%   
Avg. sales/employee Rs Th8,441.36,956.1 121.4%   
Avg. wages/employee Rs Th2,163.6902.5 239.7%   
Avg. net profit/employee Rs Th1,173.1-1,993.0 -58.9%   
INCOME DATA
Net Sales Rs m5,63919,477 29.0%  
Other income Rs m1,718407 422.0%   
Total revenues Rs m7,35719,884 37.0%   
Gross profit Rs m-631,103 -5.7%  
Depreciation Rs m252,519 1.0%   
Interest Rs m555,227 1.1%   
Profit before tax Rs m1,575-6,236 -25.3%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m792-125 -632.3%   
Profit after tax Rs m784-5,580 -14.0%  
Gross profit margin %-1.15.7 -19.6%  
Effective tax rate %50.32.0 2,503.1%   
Net profit margin %13.9-28.7 -48.5%  
BALANCE SHEET DATA
Current assets Rs m9,52211,014 86.4%   
Current liabilities Rs m3,29632,060 10.3%   
Net working cap to sales %110.4-108.1 -102.2%  
Current ratio x2.90.3 840.9%  
Inventory Days Days3795 38.6%  
Debtors Days Days2834 84.7%  
Net fixed assets Rs m4629,440 0.2%   
Share capital Rs m123705 17.5%   
"Free" reserves Rs m7,2132,043 353.1%   
Net worth Rs m7,3363,800 193.1%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m11,10546,510 23.9%  
Interest coverage x29.5-0.2 -15,267.5%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.50.4 121.3%   
Return on assets %7.6-0.8 -993.9%  
Return on equity %10.7-146.9 -7.3%  
Return on capital %22.2-3.7 -595.1%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m617,513 0.8%   
Fx outflow Rs m3,6305,649 64.3%   
Net fx Rs m-3,5701,865 -191.5%   
CASH FLOW
From Operations Rs m1,6101,682 95.7%  
From Investments Rs m687-9,860 -7.0%  
From Financial Activity Rs m-2,6776,644 -40.3%  
Net Cashflow Rs m-380-1,535 24.7%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 4.6 43.5%  
FIIs % 1.6 3.3 48.5%  
ADR/GDR % 0.0 4.6 -  
Free float % 21.5 55.3 38.9%  
Shareholders   41,647 84,811 49.1%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   PLETHICO PHARMA  BIOCON LTD  J.B.CHEMICALS  ALKEM LABORATORIES  DIVIS LABORATORIES  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 21, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS